Pharmaceuticals

Primary Sclerosing Cholangitis Market is Estimated to Witness High Growth Owing to Opportunity to Treat Associated Symptoms

Purvaja

Primary Sclerosing Cholangitis Market is Estimated to Witness High Growth Owing to Opportunity to Treat Associated Symptoms

Primary sclerosing cholangitis (PSC) is a chronic and rare liver disease characterized by progressive inflammation and scarring of the bile ducts within the liver. PSC causes bile duct injury which leads to bile-duct narrowing and bile build-up. If left untreated, it can lead to serious complications such as liver failure, cancer and ultimately liver transplant may be required. The disease often occurs in patients with ulcerative colitis, an inflammatory bowel disease. Medications help to treat the symptoms associated with PSC such as itching, infections of the bile ducts, abnormal blood tests, and fatigue.

The global Primary Sclerosing Cholangitis Market is estimated to be valued at US$ 1.98 Mn in 2023 and is expected to exhibit a CAGR of 7.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity

An early diagnosis and treatment of PSC related symptoms provides a major market opportunity. Symptomatic medical therapies help alleviate disease burden and improve the quality of life for patients. Novel drug candidates targeting PSC pathogenesis are also being explored which will likely address the unmet need to slow disease progression. Development of safe and effective therapies for PSC represents a lucrative opportunity area for pharmaceutical companies to capitalize. Overall, the need to better manage PSC symptoms and disease course offers scope for sustained market growth over the forecast period.

Porter’s Analysis

Threat of new entrants: The primary sclerosing cholangitis market has moderate threat from new entrants due to high capital requirement for R&D of novel drugs and therapies.

Bargaining power of buyers: The bargaining power of buyers is low as treatment options are limited for primary sclerosing cholangitis.

Bargaining power of suppliers: Suppliers have moderate bargaining power due to presence of few established manufacturers with patented drugs and therapies.

Threat of new substitutes: Threat from new substitutes is low as there are limited treatment alternatives available for primary sclerosing cholangitis.

Competitive rivalry: The market witnesses high competitive rivalry due to presence of major companies focusing on development of novel therapies.

SWOT Analysis

Strength: Growing research on understanding disease pathology and development of novel treatment options. Rising awareness about early diagnosis and management.

Weakness: Lack of approved drugs for long term management. High cost of therapies limiting access.

Opportunity: Collaboration between industry and research institutes to develop effective drugs. Emerging role of biomarkers and diagnostic techniques.

Threats: Long approval timelines for new drugs. Risk of disease progression despite treatment.

Key Takeaways

The global Primary Sclerosing Cholangitis Market Demand is expected to witness high growth. The increasing research activities for developing novel treatment options and diagnosis are driving the market. The global primary sclerosing cholangitis market is estimated to be valued at US$ 1.98 Mn in 2023 and is expected to exhibit a CAGR of 7.6% over the forecast period 2023 to 2030.

Regional analysis: North America dominated the market and is expected to continue its dominance over the forecast period. Presence of established healthcare infrastructure and major market players in the region drive the market. Asia Pacific is anticipated to grow at fastest pace owing to rising patient pool, increasing healthcare expenditure and improving access to diagnosis and treatment.

Key players operating in the primary sclerosing cholangitis market are Acorda Therapeutics, Inc., Gilead Sciences, Inc., NGM Biopharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., Dr. Falk Pharma GmbH, Allergan Plc., Shire Plc., Durect Corporation, Conatus Pharmaceuticals, Inc., Sirnaomics, Inc., and Shenzhen HighTide Biopharmaceutical Ltd. Key players are focusing on partnerships for development and commercialization of novel drugs for the condition.

Get more insights on this topic: https://www.pressreleasebulletin.com/primary-sclerosing-cholangitis-market-size-and-share/

Purvaja

Primary Sclerosing Cholangitis Market Will Grow At Highest Pace Owing To Increasing Investment In Advance Drugs Development

Ashish Thapa 2024-02-22

The primary sclerosing cholangitis (PSC) market is characterized by inflammatory and fibrotic strictures of the bile ducts leading to cholestasis. 29 Mn in 2024 and is expected to exhibit a CAGR of 5. Impact of COVID-19 on Primary Sclerosing Cholangitis Market GrowthThe COVID-19 pandemic has significantly impacted the growth of the Primary Sclerosing Cholangitis Market Demand. However, with the gradual lifting of lockdowns and development of COVID vaccination programs, the primary sclerosing cholangitis market is recovering. Fastest Growing Region for Primary Sclerosing Cholangitis MarketAsia Pacific region is poised to witness the fastest growth in the primary sclerosing cholangitis market over the forecast period.

Primary Sclerosing Cholangitis: A Rare but Serious Liver Disease

Poonam 2024-03-04

What is Primary Sclerosing Cholangitis? Causes and Risk Factors While the exact cause of Primary Sclerosing Cholangitis remains unknown, it is considered an autoimmune disease. Other potential risk factors include smoking, primary sclerosing cholangitis, liver flukes and infections such as salmonella. In summary, Primary Sclerosing Cholangitis is a chronic inflammatory condition affecting the bile ducts. Get more insights, On Primary Sclerosing Cholangitis

Primary Sclerosing Cholangitis Market Growth Expands Opportunities

Sneha 2023-11-06

The global Primary Sclerosing Cholangitis Market is estimated to be valued at US$ 3,604. 6% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights. Key Takeaways:-The Global Primary Sclerosing Cholangitis Market Size is expected to witness high growth, exhibiting CAGR of 4. North America dominated the global market in 2022 and is projected to maintain its dominance over the forecast period. Key players operating in the Primary Sclerosing Cholangitis market include Acorda Therapeutics Inc.

Primary Sclerosing Cholangitis Market Growth Accelerated by Increasing Disease Prevalence

Pooja salve 2023-12-22

The global Primary Sclerosing Cholangitis Market is estimated to be valued at US$ 1. The growing patient pool of inflammatory bowel disease therefore is presenting a strong growth opportunity for the primary sclerosing cholangitis market during the forecast period. Key Takeaways Global Primary Sclerosing Cholangitis Market Demand is expected to witness high growth over the forecast period. The global Primary Sclerosing Cholangitis Market is estimated to be valued at US$ 1. Key players Key players operating in the primary sclerosing cholangitis market are Abbott Point of Care Inc. com/primary-sclerosing-cholangitis-market-demand-analysis-and-value-insights/ Check below trending articles on this topic- https://careersplay.

Global Primary Biliary Cholangitis Treatment Market Analysis

Ben Wood 2023-03-20

The bile ducts gradually deteriorate in primary biliary cholangitis, sometimes referred to as primary biliary cirrhosis, a chronic liver disease. It is predicted that the Primary Biliary Cholangitis Treatment Market would expand faster due to the increasing frequency of primary biliary cholangitis worldwide. There are four stages of primary biliary cholangitis, from stage 1 (no scarring) to stage 4. Due to increasing efforts by industry participants to provide cutting-edge treatment options for PBC, North America is predicted to see profitable primary biliary cholangitis treatment market expansion. For instance, the TARGET-PBC (Primary Biliary Cholangitis) platform was introduced in October 2016 by the US company TARGET PharmaSolutions, Inc.

The global primary sclerosing cholangitis market Growth Accelerated by the Rising Prevalence of Primary Sclerosing Cholangitis

Niranjan Mardakar 2024-01-17

According to a study, the prevalence of primary sclerosing cholangitis varies from 0 to 16. With growing awareness, early detection is improving which is leading to the growth of the primary sclerosing cholangitis market. The primary sclerosing cholangitis market is primarily segmented into drug class and end-users. The global primary sclerosing cholangitis market is estimated to be valued at US$ 250 million in 2023 and is expected to exhibit a CAGR of 5% over the forecast period 2023 to 2030. Regional analysis: North America is currently the dominant region in the primary sclerosing cholangitis market due to the high prevalence of inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease in the region.

WHO TO FOLLOW